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Abstract
Purpose: Fluorescence guidance in surgical oncology provides the potential to realize enhanced
molecular tumor contrast with dedicated targeted tracers, potentially with a microdose injection
level. For most glioma tumors, the blood brain barrier is compromised allowing some exogenous
drug/molecule delivery and accumulation for imaging. The aberrant overexpression and/or
activation of epidermal growth factor receptor (EGFR) is associated with many types of cancers,
including glioblastoma, and so the use of a near-infrared (NIR) fluorescent molecule targeted to
the EGFR receptor provides the potential for improving tumor contrast during surgery.
Fluorescently labeled affibody molecule (ABY-029) has high EGFR affinity and high potential
specificity with reasonably fast plasma clearance. In this study, ABY-29 was evaluated in glioma
versus normal brain uptake from intravenous injection at a range of doses, down to a microdose
injection level.
Procedure: Nude rats were inoculated with the U251 human glioma cell line in the brain. Tumors
were allowed to grow for 3–4 weeks. ABY-029 fluorescence ex vivo imaging of brain slices was
acquired at different time points (1–48 h) and varying injection doses from 25 to 122 μg/kg (from
human protein microdose equivalent to five times microdose levels).
Results: The tumor was most clearly visualized at 1-h post-injection with 8- to 16-fold average
contrast relative to normal brain. However, the tumor still could be identified after 48 h. In all
cases, the ABY-029 fluorescence appeared to localize preferentially in EGFR-positive regions.
Increasing the injected dose from a microdose level to five times, a microdose level increased
the signal by 10-fold, and the contrast was from 8 to 16, showing that there was value in doses
slightly higher than the microdose restriction. Normal tissue uptake was found to be affected by
the tumor size, indicating that edema was a likely factor affecting the expected tumor to normal
tissue contrast.
Conclusion: These results suggest that the NIR-labeled affibody molecules provide an excellent
potential to increase surgical visualization of EGFR-positive tumor regions.
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Introduction
Glioblastoma is the most aggressive and the most common
type of brain malignant tumors in adults with an average
survival of 12 months after diagnosis. This poor prognosis is
due to the fast growth and highly infiltrative feature of
glioma cells, which are able to migrate from the main tumor
mass and invade the normal brain parenchyma [1–4].
Preoperative imaging does not always clearly define the
edge of the tumor because of this infiltration, and the
presence of a positive margin after surgery contributes to
frequent recurrence rates [5]. In this study a new contrast
agent consisting of a fluorescently labeled Affibody mole-
cule that binds to the epidermal growth factor receptor
(EGFR) was examined for uptake in orthotopic glioma
tumors to assess the contrast available to guide surgery.
Several recent studies have demonstrated the use of
intraoperative fluorescent imaging as a tool to overcome
some limitations of conventional white light surgery, to
enhance the visual contrast between tumor and normal tissue
[6–10]. Oral administration of 5-ALA induces PpIX fluo-
rescence in high grade glioblastoma tumors, which can be
imaged during fluorescent-guided surgery (FGS). This has
been adopted clinically in several countries, following
success reported in both preclinical and clinical trials.
However, the observed PpIX accumulation is thought to be
partially due to the blood brain barrier breakdown, allowing
the ALA to leak through, which can be less pronounced in
the tumor edges [11, 12]. In comparison, exogenous protein
targeting has allowed identification of several biomarkers
which are overexpressed in many types of cancer such as the
cell surface receptors EGFR and VEGFR [13–17] which
have been studied as targets for therapeutic drug delivery
[18–20] and diagnostic imaging [21–23]. Rosenthal and
collaborators (2015) described the results of the first-in-
human clinical trial using cetuximab conjugated to IRDye®
800CW to guide the surgery of head and neck squamous cell
carcinoma and the fluorescence was correlated to EGFR
expression of the tumor. The tumor-to-background contrast
was dose-dependent, although there was evidence of
receptor saturation at higher dose. However, because of the
long biological half-life of antibodies, the tumor-to-normal
contrast increases over time [24].
In this study, fluorescently labeled affibody molecules
(Affibody, Solna, Sweden) targeting EGFR have been
developed for human use. Affibody molecules are small
proteins (derived from a 58 amino acids long Z-domain
scaffold) [25]. The EGRF-binding affibody molecules were
engineered with a maleimide linker for site-specific cysteine
conjugation with a fluorescent dye such that fluorophore
labeling does not interfere with the binding domain site for a
receptor, thereby maintaining binding affinity. These mole-
cules have high affinity (approximately Kd ~ 2.8 nM) and
demonstrate localization in glioma tumors [13, 26]. Due to
their small size, affibody molecules present fast clearance
from the blood and reasonable diffusion through tissue,
which are the desirable features for a high-contrast surgical
imaging agent [25].
In a study performed by Lee and colleagues, the tumor
accumulation of an anti-HER2 affibody conjugated to Alexa
Fluor® 750 was evaluated. The results showed its potential
as a probe for in vivo imaging of HER2-positive breast
cancer [27]. In a previous study, Sexton et al. showed that
the accumulation of an anti-EGFR affibody, conjugated to
IRDye® 800CW, was higher in rodent glioma tumors than
the anti-EGFR antibody cetuximab conjugated to IRDye®
680RD. The anti-EGFR affibody molecule was present in
the tumor periphery whereas the anti-EGFR antibody was
primarily localized in the central portion of the tumor [26].
In the present study, the tumor uptake of pre-GMP ABY-029
was evaluated for the contrast in tumor-to-normal brain, as a
function of time and administered dose.
Experimental Session
Reagents
Anti-EGFR affibody molecules were manufactured under contract
from Affibody AB (Solna, Sweden); IRDye® 800CW maleimide
was specially produced by LI-COR Biosciences (Lincoln,
Nebraska). The anti-EGFR affibody molecules labeled with
IRDye® 800CW have been developed by Bachem and named
pre-GMP ABY-029.
Cell Culture
The human glioblastoma cell line U251 was obtained from Dr.
Mark Israel (Norris Cotton Cancer Center, Dartmouth-Hitchcock
Medical Center, Lebanon, NH, USA) and cultured in DMEM
supplemented with 10 % fetal bovine serum and 100 IU/ml
penicillin-streptomycin. The cells were subcultivated at 80–90 %
of confluence.
Orthotopic Implantation in Nude Rats
All animal studies were approved by Dartmouth College
Institutional Animal Care and Use Committee (IACUC) and
conducted in accordance with all institutional Public Health
Service (PHS) and Office of Laboratory Animal Welfare (OLAW)
guidelines.
Forty-eight female nude rats (6–8-week old) were used. The
U251 cell line was chosen due to its clinically relevant level of
EGFR expression. The animals were anesthetized using isoflurane
(2 % and 1 l/min oxygen) and an incision was made in the scalp,
with the brain accessed by a 1-mm rotary drill to create a burr hole.
Guided using a stereotaxic frame (Stoelting Co, Wood Dale, IL,
USA), the 1 × 106 cells in 5 μl phosphate-buffered saline (PBS)
were injected at a 3-mm depth into the left cerebral hemisphere of
the rats, 3 mm posterior to the bregma, using a Hamilton syringe
(Hamilton Company, Reno, NV). The cells were injected over a 5-
min period, and the needle slowly retracted from the brain. Bone
wax (Ethicon, Inc., Piscataway, NJ, USA) was used to close the
42 de Souza A.L.R. et al.: Time-Dose Analysis of an EGFR-Directed Affibody Molecule
hole in the skull and the incision in the scalp closed, using 5–0
sterile non-absorbable suture material (Ethicon, Inc., Piscataway,
NJ, USA).
A control group received an identical procedure without tumor
cells (saline only).
Magnetic Resonance Imaging
Contrast-enhanced magnetic resonance imaging was used to
monitor tumor growth in the brain. In these studies, the rats were
anesthetized with isoflurane and maintained at a surgical anesthesia
plane through the procedure. A Phillips Achieva 3.0T X-series MRI
with a modified rodent coil (Philips Research Europe, Hamburg,
Germany) was used [23]. T1- and T2-weighted turbo-spin echo
images were acquired prior to intravenous administration of
0.1 mmol of gadolinium Gd-DTPA (Magnevist®) and the post-
contrast T1W image sequence was collected 10 min following
gadolinium injection. The T2W image sequence was collected
during the contrast uptake. The MRI images were processed and
analyzed using NIRFAST Software (Version 1.12) [28, 29].
Fluorescent Tracer Imaging Experiments
Two weeks post-tumor cell inoculation, the rats received a non-
fluorescent diet (Purified Mouse Diet, MP Biomedicals, LLC,
Illkirch, France) to reduce auto-fluorescence from chlorophyll
contained in regular chow. Three to 4 weeks post-tumor inocula-
tion, rats were randomly divided into 10 experimental groups to
either receive different doses of ABY-029 (24.5, 49.0, or 122.5 μg/
kg) at different time points (1–48 h) or PBS (control group). The
lowest dose, 24.5 μg/kg, corresponds to the human equivalent
microdose for a protein molecule, defined by the FDA as ≤30
nanomoles (Guidance for Industry, Investigators, and Reviewers-
Exploratory IND Studies, 2006). After the predetermined time, the
animals were euthanized by cervical dislocation; the brain was
removed and sectioned into 2-mm thick slices. Three U251
inoculated rats and two sham rats, for each group, were used.
Fluorescence images from the sequential brain sections were
acquired by scanning the 2-mm thick slices on the Odyssey Infrared
Imaging System (LI-COR Biosciences) using the 800-nm channel,
at 21-μm lateral spatial resolution. Eight to ten slices from each rat
were examined in a single scan, and completed within minutes of
brain removal.
For fluorescence image contrast analysis, the relative difference
between the fluorescence intensity in the tumor and normal brain
tissue was calculated according to the equation:
Contrast ¼ FT−FNð Þ
FN−FBð Þ
where F is the region of interest (ROI) fluorescence from tumor
(FT) and contralateral normal (FN) brain quantified in ImageJ®
software (NIH, Bethesda, MD), and background being outside the
brain region (FB). The ROI of both tumor region and contralateral
normal brain was guided by custom delineation based upon the
fluorescence images and confirmed with the hematoxylin and eosin
images.
Hematoxylin and eosin and Immunohistochemistry
Staining and Microscopy Analysis
Following analysis of the fluorescence in the brain sections, the
samples were fixed overnight in 4 % neutral buffered formalde-
hyde. Research Pathology Services at the Geisel School of
Medicine at Dartmouth College prepared the following histopa-
thology and immunohistochemistry tissue sections. Formalin-fixed
tissues were dehydrated using crescent concentrations (70–100 %)
of alcohol (Fisher Scientific, USA), cleared with xylene (Cat #
X3P-1GAL, Fisher Scientific, USA) and embedded in paraffin (Cat
# 7052, Sakura Finetek, Torrance, CA, USA). The brain sections
were cut to 4-μm thickness and stained with hematoxylin and eosin
(H&E) and for total EGFR using an anti-EGFR primary antibody
(EP38Y) (Cat # ab52894; Abcam Inc., Cambridge, MA, USA)
(immunohistochemistry).
Whole brain images were acquired using a light microscope
(Zeiss, Stemi SV 11 APO) at ×0.6 magnification. ROI of tumor and
normal tissue were analyzed at ×10 magnification (Olympus-
BX50).
Statistical Analysis
Statistical analysis was performed using OriginPro® 8 software
(OriginLab, Wellesley Hills, MA, USA). Student’s paired t test was
performed to determine statistical significance of the difference in
signal between the tumor regions and corresponding contralateral
brain or animals undergoing sham surgery. Statistics assessment
was also used to determine the difference between different doses
and time points. Linear regression was used to compare the size of
the tumor and contralateral normal brain fluorescence. This
information was reported as a Pearson correlation coefficient (r).
Results were considered statistically significant at a P G 0.05.
Results
Pre-GMP ABY029 uptake was evaluated using an infrared
imaging system and the level of fluorescence from rat ex vivo
brain slices was acquired at different time points post-injection.
Figure 1 presents the 1:1 correlation of whole brain fluores-
cence and H&E histologic staining. This co-registration
demonstrates a high correlation between tumor presence and
fluorescence.
There was high fluorescence heterogeneity, within and
around the tumors (Fig. 2a). Histograms of the tumor
fluorescence, shown in Fig. 2b, demonstrate the regular
presence of two regions of intensity. The regions of high
ABY-029 fluorescence intensity were often well correlated
to the regions of high EGFR expression, as illustrated by
ex vivo staining using anti-EGFR antibodies in Fig. 2d.
The EGFR-specific staining confirms the localization
patterns expected; however, it is important to note that
low level ABY-029 fluorescence is still visible in the
regions with lower EGFR-specific staining with antibodies.
Another feature evaluated in this study was the ability of
ABY-029 to recognize positive margins in which migratory
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cells are presented (Fig. 3). Tumor cells cannot only migrate
through blood vessels to infiltrate the normal brain, but also
can be derived from the main tumor mass and migrate in
surrounding brain tissue as seen by ABY-029 fluorescence
in Fig. 3a.
The effect of dose escalation and temporal analysis of the
fluorescence is demonstrated in Fig. 4. The peak of
fluorescence in tumors is observed at early times (1–4 h)
in a dose-dependent manner and there is significant
fluorescence in the glioma tumors for several hours after
injection. Moreover, fluorescence in the tumor regions was
significantly higher than in the contralateral normal brain, or
in the brains of rats that received a sham surgery.
Figure 5a, b presents the fluorescence signal intensity
from contralateral normal brain as a function of the tumor
area detected by the lowest and highest dose of the pre-GMP
ABY-029. There are no statistically significant fluorescence
trends for tumor size in the 1× microdose group; however,
there is a significance when the dose is elevated fivefold.
A strong positive linear correlation (r = 0.91 and r = 0.74
for 1 h and 24 h post-injection, respectively) (P G 0.05 for
Pearson correlation) was determined to five times the
microdose, likely from edema in the normal brain (Fig. 5c).
The success of a fluorescence-guided brain surgery is
highly dependent of the tumor-to-normal brain fluorescence
contrast, and the results are presented in Fig. 6. The contrast
relative to the normal brain is dependent on the dose given
and the time of data acquisition after dose administration. In
our study, the contrast varied from 7 to 16 in the first 4 h.
After 24 h, in the microdose level, the contrast is reduced by
a factor of 3 to 2.7 resulting in a very low fluorescence
intensity. However, with higher administered ABY-029
doses (two or five the microdose level), the contrast level
decreased only slightly over time.
Discussion
Several published studies have tested the concept of a
receptor-binding molecule, conjugated to a near-infrared
fluorescent probe that is able to be localized in the margin of
tumor and normal tissue. The goal of this and similar
research is to increase the tumor-to-background contrast
ratio as a means of improving the tumor delineation during
surgical resection, and to determine if injection at the
microdose level was a reasonable administration concentra-
tion to achieve this. In 2011, van Dam and colleagues
studied the use of folate conjugated to fluorescein isothio-
cyanate (FITC) to target the folate receptor α (FR-α)
overexpressed in ovarian cancer. This receptor-targeting
fluorescent probe demonstrated a promising approach for
detection of the receptor positive human tumors compared to
the conventional visual inspection during standard surgery
Fig. 1. Multiple plane co-registration of brain tumor morphology (a, d) and ABY-029 fluorescence (b, c) in a series of brain
slices from the same rat. The tumor regions are fairly obvious in the H&E, and are circled in the lower left H&E images, which
correlate well with the fluorescence areas. Each row from columns a and b or c and d correspond to the same slice of the brain
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[30]. In neurosurgery, substantial efforts have been made
with the metabolic marker protoporphyrin IX produced by
mitochondrial heme synthesis [31–34], and indocyanine
green perfusion imaging [35–37] to delineate the tumor
borders during brain surgery. Based on this basic research,
dedicated surgical microscope systems are now commer-
cially available for fluorescence image acquisition in either
the red (600–750 nm) or near-infrared (800+ nm) wave-
length bands [38].
In this study, the tumor uptake of ABY-029 was
examined as a function of its administered dose and time
after injection. The co-localization of the tumor microenvi-
ronment and Affibody-fluorescent probe signal was ob-
served through bulk analysis (Figs. 1, 2, and 3). However,
the distribution of the fluorescence signal in the tumor was
also documented to be highly heterogeneous (Fig. 2). This
results from cellular heterogeneity and differentiation level
of the glioma cells [39], and/or the spatial and temporal
heterogeneity of the blood supply, leading to high delivery
variability from the enhanced permeability and retention
effect [40, 41]. The absence of fluorescence usually was
observed in the tumor interior and it could be either
correlated with necrotic areas (Fig. 2c inset), in which
vascular supply is often inadequate or insufficient, or lower
interstitial pressure present in peripheral areas of the tumor
that allows leakage of macromolecules [40]. Perhaps most
importantly, the EGFR overexpression was documented by
ex vivo staining with an independent antibody, and the
presence of hot spots staining of ABY-029 appeared to be
well correlated to the EGFR density (Fig. 2d inset).
Glioma cells are highly infiltrative i.e., they have the
ability to migrate from the main tumor mass to the normal
tissue surrounding the margins of the tumor. The accurate
anatomical delineation of the tumor boundaries during
surgery is challenging, and it is extremely important for the
clinical success in the surgery. In this study, ABY-029
fluorescence was seen in tumor cells at the margin of main
tumor mass (Fig. 3).
One point to be considered is the fact that EGFR is also
highly expressed in some normal tissues, such as the liver,
Fig. 2. a The distribution of ABY-029 fluorescence in the tumor region immediately after tissue removal. b The heterogeneity of
fluorescence signal distribution for each corresponding slice. c The H&E-stained tissue. d The EGFR-stained tissue. This
information illustrates the true EGFR expression patterns.
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skin, and submaxillary salivary gland. Therefore, the
bioavailability of ABY-029 could be reduced as a conse-
quence of off-target EGFR binding of the NIR probe. The
results from dose escalation showed a dose-dependent ABY-
029 tumor uptake (Fig. 4), which can be related to saturation
of EGFR in the liver [42]. Moreover, the fluorescence from
the tumor was higher than the contralateral normal brain or
brain from the rats that received sham surgery. This was true
even 48 h post-injection. Thus, these results show that there
is high in vivo specificity for ABY-029 uptake by tumor
cells.
An interesting result observed in this study was the
increase in the contralateral normal brain fluorescence as a
function of tumor area for the animals that received 5-fold
larger dose than the initial dose (Fig. 5b), which could be
correlated to the transport, likely due to edema, leading to
nearly 10-fold higher uptake in the tumor, and approxi-
mately a 2-fold increase in tumor to normal tissue contrast.
Curiously, at the lower injected dose of 24.5 μg/kg, the
increase in normal brain uptake with tumor size was not as
apparent, but this could have been due to the lower leakage
rates into the tissue from lower concentration. In the cases of
Fig. 3. These images represent the presence of fluorescent (EGFR) tumor cells at the margin of the primary tumor mass. aEx
vivo fluorescence analysis. b H&E staining (×0.6 magnification). c H&E staining (×10 magnification) and visualization of tumor
cells migrating into normal brain tissue. The last row corresponds to sham surgery and, therefore, serves as a control brain
tissue.
Fig. 4. Normalized fluorescent signals are shown for all tumor and normal tissues slices analyzed, at all three dose levels (24.5,
49, 122.5 μg/kg), and at varying times following injection (1 h up to 24 h or 48 h). *P G 0.05, Student’s t test.
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larger tumors, the ABY-029 uptake in the background
normal brain presented in the extracellular matrix by the
cerebrospinal fluid to intact areas of the brain, as seen in
Fig. 5c. Similar results have been documented with PpIX
fluorescence imaging near glioma tumors [43]. More
importantly, though, this increased background from
edema-based perfusion to normal brain did not significantly
decrease the tumor -to-normal contrast (Fig. 6), and a high
contrast could be seen even after 24 h post-injection, which
is important to cover all possible times for surgical use.
Conclusion
ABY-029 can be used in intraoperative fluorescent-guided
surgery of glioma in order to improve detection of the
tumor-to-normal tissue boundary and decrease the residual
tumor cells surrounding the tumor margin, which is the key
to improved prognosis of following resection of glioblas-
toma. The value of increasing the injected dose above a
microdose appears clear, providing significant 2-fold in-
crease in contrast and also a longer term increase extending
out to 24 h. However, it is possible to see contrast in glioma
tumors with injected doses as low as a standard FDA
microdose level. GMP production of ABY-029 is in
progress, and toxicological studies have been completed to
confirm the safety of the molecular-targeted fluorescent
probe for future clinical trial [44].
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Fig. 5. Fluorescence from the contralateral normal brain as a function of the observed tumor size for a microdose (24.5 μg/kg)
and b five times the microdose (122.5 μg/kg); 1 h (closed symbols) and 24 h (open symbols) post-injection. The lines
correspond significant trends observed from linear regression. c T1 (left) and T2 (right) MRI of a U251 tumor-bearing rat post-
gadolinium injection. The tumor (T) can be seen as a focal region in the T1, with peri-tumor edema (E) in the T2 image.
Fig. 6. The tumor-to-normal brain contrast values are
expressed as mean values ± standard error of mean using
the ratio of data from Fig. 4 for each injection concentration
and time point studied.
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